The I-SPY2 trial (NCT01042379) is a multicentre, phase 2 trial where patients with HER2-negative breast cancer were randomized to receive neoadjuvant cemiplimab plus REGN3767 and paclitaxel or weekly paclitaxel for 12 cycles. In this touchONCOLOGY interview, we speak with Prof. Claudine Isaacs (Georgetown University, Washington, DC, USA) who gives an overview of the I-SPY2 study with the rationale for the use of cemiplimab plus REGN3767 as well as discussing the aims, design and findings of the study.
The abstract entitled ‘Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
Questions:
- Could you give us a brief overview of the I-SPY2 study? (0:20)
- What is the rationale for the use of cemiplimab and fianlimib in women with breast cancer? (1:11)
- What were the aims, design and eligibility criteria of this I-SPY 2 substudy? (3:27)
- What were the efficacy and safety findings of the study? (4:28)
- Which women are most likely to benefit from this regimen? (9:17)
Disclosures: Claudine Isaacs is a consultant for Genentech, PUMA, Seattle Genetics, AstraZeneca, Novartis, Pfizer, ESAI, Sanofi, ION and Gilead and discloses grant/research support from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech and Novartis.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
